TruAlt promoter group buys 21,600 shares for ₹1 crore

1 min read     Updated on 07 Aug 2026, 04:59 PM
scanx
Reviewed by
Naman SScanX News Team
AI Summary

Nirani Holdings Private Limited, part of TruAlt Bioenergy's promoter group, bought 21,600 shares worth ₹1 crore on August 5, 2026. This increases its stake to 1.45%, complying with SEBI PIT Regulations.

powered bylight_fuzz_icon
47647745

*this image is generated using AI for illustrative purposes only.

Nirani Holdings Private Limited (NHPL), a member of the promoter group of trualt bioenergy , has increased its stake in the company by acquiring 21,600 equity shares from the open market. The acquisition, executed on August 5, 2026, signals continued confidence from the promoter group in the listed entity’s prospects. The transaction was completed at an average price of ₹462.98 per share, aggregating to a total value of ₹1,00,00,363, excluding taxes and brokerage charges.

The purchase raises NHPL’s total holding in TruAlt Bioenergy Limited from 12,23,830 shares (1.43%) to 12,45,430 shares (1.45%). The shares were credited to the Demat account of NHPL following the trade on the National Stock Exchange of India Limited (NSE). The disclosure was submitted to the stock exchanges on August 7, 2026, pursuant to Regulation 7(2) of the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015.

Transaction Details

The following table outlines the specifics of the shareholding change as reported in Form C:

Particulars Details
Acquirer Nirani Holdings Private Limited
Category Promoter Group
Shares Acquired 21,600 Equity Shares
Average Price ₹462.98
Total Value ₹1,00,00,363
Transaction Date August 5, 2026
Pre-Acquisition Stake 12,23,830 shares (1.43%)
Post-Acquisition Stake 12,45,430 shares (1.45%)
Exchange NSE

Regulatory Compliance

The disclosure was signed by Vijaykumar Nirani, Director of NHPL, and submitted to the Company Secretary and Compliance Officer of TruAlt Bioenergy Limited on August 6, 2026. Monu Kumar, Company Secretary and Compliance Officer of TruAlt Bioenergy Limited, forwarded the disclosure to BSE Limited and NSE on August 7, 2026. The filing confirms that the transaction was conducted through the stock exchange on an 'on-market' basis, adhering to the continual disclosure requirements under Regulation 6(2) read with Regulation 7(2) of the SEBI (PIT) Regulations, 2015. No derivatives trading by the promoter group was reported in this disclosure.

Historical Stock Returns for Trualt Bioenergy

1 Day5 Days1 Month6 Months1 Year5 Years
+2.75%+9.47%+3.68%+11.90%-10.15%-10.15%

Will the promoter group's increased stake trigger further open-market acquisitions to consolidate control or signal upcoming strategic initiatives?

How might this incremental buy-in influence retail investor sentiment and short-term trading volume for TruAlt Bioenergy shares?

Does this acquisition align with TruAlt Bioenergy's broader capital structure plans, such as potential debt reduction or equity financing needs?

TruAlt Bioenergy Q1 Results: Net profit rises 14% YoY to ₹591 crore

1 min read     Updated on 07 Aug 2026, 04:08 PM
scanx
Reviewed by
Naman SScanX News Team
AI Summary

Britannia Industries posted a 13.6% YoY net profit rise to ₹591 crore in Q1FY27, missing estimates due to input cost inflation. Revenue grew 8.2% to ₹5,000 crore, with EBITDA up 11% to ₹840 crore. Margins improved slightly to 16.8%, supported by volume-price mix and e-commerce scaling.

powered bylight_fuzz_icon
47644728

*this image is generated using AI for illustrative purposes only.

Britannia Industries reported a 13.6% year-on-year rise in consolidated net profit to ₹591 crore for the June quarter (Q1) of FY27, driven by volume and price increases across key categories. Despite the growth, the company missed street estimates of ₹606 crore, citing inflationary pressures in fuel and logistics amid geopolitical uncertainty. Consolidated revenue from operations increased 8.2% year-on-year to ₹5,000 crore, in line with market expectations of ₹4,999 crore.

Earnings before interest, tax, depreciation, and amortisation (EBITDA) rose 11% year-on-year to ₹840 crore, though this fell short of the estimated ₹871 crore. EBITDA margins expanded marginally to 16.8% in Q1FY27 compared to 16.4% in the corresponding period of FY26. Total expenses stood at ₹4,262.24 crore, reflecting a 7.27% year-on-year increase. The company noted that it is gaining ground against local rivals, with positive sequential momentum anchored by rapid scaling in e-commerce and robust growth in general trade.

Financial Performance

Metric Q1FY26 (₹ cr) Q1FY27 (₹ cr) YoY Change (%)
Revenue from Operations 4,622 5,000 +8.2
EBITDA 757 840 +11.0
Net Profit 521 591 +13.6
EBITDA Margin (%) 16.4 16.8 +0.4

The company’s international business recovered sequentially as supply chain constraints began normalising in the latter part of the quarter. Britannia derives approximately 93-95% of its revenue from domestic operations, with international businesses contributing 5-7%. Rakshit Hargave, CEO & MD of Britannia Industries, stated that higher advertisement, influencer, and promotional spends aided growth. He added that the company will remain agile to deliver sustainable revenue growth amid improving domestic demand, driven by sharp innovation and disciplined margin management.

What the Numbers Show

While top-line growth was strong at 8.2%, the miss in net profit against estimates highlights the impact of input cost inflation. The slight expansion in EBITDA margins to 16.8% suggests some success in passing on price increases, but the gap between actual and estimated earnings indicates persistent pressure from fuel and logistics costs. The sequential recovery in international operations provides a potential upside, though this segment remains a small contributor to overall revenue.

Historical Stock Returns for Trualt Bioenergy

1 Day5 Days1 Month6 Months1 Year5 Years
+2.75%+9.47%+3.68%+11.90%-10.15%-10.15%

How might Britannia adjust its pricing strategy in Q2FY27 to offset persistent fuel and logistics inflation without compromising volume growth?

What specific innovations is Britannia prioritizing to maintain its competitive edge against local rivals in the general trade segment?

Could the sequential recovery in international operations accelerate significantly in the coming quarters, or will supply chain normalization remain gradual?

More News on Trualt Bioenergy

1 Year Returns:-10.15%